Combining multiple samples into a single experiment increases cost efficiency and productivity
Enables scaling to advance cell and gene therapy, precision medicine, and biomarker programs
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform. These features enable the combination of several samples into a single run, reducing the per-sample costs for single-cell DNA and protein multiomic analysis by up to 60% to provide increased access. By allowing researchers to simultaneously process multiple samples, the new capabilities are designed to offer biopharma companies opportunities for optimizing product characterization and drug development and provide academic researchers the ability to scale critical single-cell insights, particularly in oncology and genome editing fields, for transformative advancements in health and disease management.
Many researchers continue to rely on conventional techniques such as PCR and cell culture due to the accessibility of these approaches, however, these techniques are laborious and offer low resolution. Despite the valuable insights that single-cell DNA and protein multiomic analysis offer, including clonal heterogeneity, evolution, mutation co-occurrence, and therapy response/resistance, costs for sample analysis are still a significant barrier to widespread usage. Combining multiple samples into a single experiment will help lower this barrier to entry for academic researchers and de-risk the adoption for biopharma.
“At Mission Bio, our goal is to empower more researchers to harness the advantages of single-cell multiomics to accelerate scientific discoveries, from academics using genome editing techniques for disease modeling to biopharma in the cell and gene therapy space,” said Anjali Pradhan, Chief Product Officer of Mission Bio. “Our new sample multiplexing features will help lower the per-sample costs of single-cell DNA sequencing and single-cell DNA + protein multiomics, so researchers can decrease resource and labor usage and achieve higher throughput and cost-efficiency without sacrificing quality.”
Two new sample multiplexing capabilities allow users to combine and analyze up to three samples per experiment. Sample multiplexing by antibody hashing, powered by antibody oligo conjugates (AOCs) from BioLegend (part of Revvity) is a widely accepted approach among the single-cell community and leverages hashtag AOCs with unique barcodes to distinguish samples. Sample multiplexing by genotyping, unique to Tapestri, uses the genetic information of the relevant variants obtained by bulk next-generation sequencing to distinguish samples.
The primary benefits of Mission Bio’s sample multiplexing include:
- Higher throughput: Multiple samples are processed in a single experiment, allowing for more statistically significant studies
- Increased cost efficiency: Sample pooling improves efficiency by minimizing hands-on time and reagent usage, and reducing per-sample costs by up to 60%
- Streamlined analysis: Automatic sample demultiplexing using the Tapestri Pipeline Software
- Consistently robust performance: Increase throughput and cost-efficiency without sacrificing quality metrics (sensitivity and specificity).
Ilaria Iacobucci, Ph.D., Principal Scientist, Department of Pathology at St. Jude Children's Research Hospital, said, “Single-cell characterization in preclinical and clinical therapeutic studies is crucial. Collecting therapeutic effects at the cellular resolution can serve as indicators of successful target inhibition and efficacy in the clinical setting, especially for pediatric cancers and hematological malignancies. Mission Bio’s multiplexing capabilities make single-cell technology more accessible to the biomedical community and has the potential to dramatically impact patient care in the future.”
For more information about Tapestri, please visit www.missionbio.com.
About Mission Bio
Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404216329/en/
Contacts
Consort Partners for Mission Bio
missionbio@consortpartners.com
